MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

Search

Bayer AG

Fermé

SecteurFinance

26.36 -0.17

Résumé

Variation du prix de l'action

24h

Actuel

Min

26.185

Max

26.425

Chiffres clés

By Trading Economics

Revenu

1.6B

1.3B

Ventes

2B

14B

P/E

Moyenne du Secteur

30.9

24.968

BPA

2.49

Rendement du dividende

0.44

Marge bénéficiaire

9.492

Employés

90,885

EBITDA

1.9B

3.6B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+0.53% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.44%

4.18%

Prochains Résultats

5 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

3.5B

25B

Ouverture précédente

26.53

Clôture précédente

26.36

Sentiment de l'Actualité

By Acuity

37%

63%

139 / 538 Classement par Finance

Score Technique

By Trading Central

Confiance

Bearish Evidence

Bayer AG Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 mai 2025, 08:22 UTC

Résultats
Principaux Mouvements du Marché

Bayer Shares Jump After Results Beat Expectations on Pharma Strength

13 mai 2025, 06:09 UTC

Résultats

Bayer Confirms Guidance Despite Net Profit Drop

24 mars 2025, 09:37 UTC

Principaux Mouvements du Marché

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

5 juin 2025, 08:29 UTC

Market Talk

Bayer Earnings Expectations Might Have Bottomed out -- Market Talk

30 mai 2025, 13:47 UTC

Market Talk
Acquisitions, Fusions, Rachats

Consumer Health Sector Has Room for More Dealmaking -- Market Talk

27 mai 2025, 12:22 UTC

Market Talk
Résultats

Bayer's Prospects Are Improving -- Market Talk

16 mai 2025, 13:42 UTC

Actions en Tendance

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16 mai 2025, 08:57 UTC

Actions en Tendance

Stocks to Watch Friday: Richemont, Bayer, Take-Two, UnitedHealth -- WSJ

15 mai 2025, 22:46 UTC

Actualités
Acquisitions, Fusions, Rachats

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mai 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 mai 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 mai 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

13 mai 2025, 06:50 UTC

Market Talk
Résultats

Bayer's Results Should Cause Positive Share Price Response -- Market Talk

13 mai 2025, 05:36 UTC

Résultats

Bayer: Sees EBITDA Margin Before Special Items of Pharma Division to Come in at Upper End of Guidance Range

13 mai 2025, 05:35 UTC

Résultats

Bayer: Sees Sales Growth of Pharma Division to Come in at Upper End of Guidance Range

13 mai 2025, 05:34 UTC

Résultats

Bayer: Currency Adjusted Basis Guidance Includes Impact From Tariffs

13 mai 2025, 05:34 UTC

Résultats

Bayer: Considerable Uncertainty Persists Concerning Future Impacts From Tariffs

13 mai 2025, 05:32 UTC

Résultats

Bayer 1Q EPS EUR2.49

13 mai 2025, 05:32 UTC

Résultats

Analysts Saw 1Q Ebitda Before Special Items at EUR3.82B

13 mai 2025, 05:32 UTC

Résultats

Bayer 1Q Ebitda Before Special Items EUR4.085B

13 mai 2025, 05:31 UTC

Résultats

Bayer 1Q EBIT EUR2.32B

13 mai 2025, 05:31 UTC

Résultats

Bayer 1Q Net Pft EUR1.30B

13 mai 2025, 05:31 UTC

Résultats

Analysts Saw Bayer 1Q Net Pft at EUR1.485B

13 mai 2025, 05:30 UTC

Résultats

Analysts Saw Bayer 1Q Sales at EUR13.41B

13 mai 2025, 05:30 UTC

Résultats

Bayer 1Q Sales EUR13.74B

13 mai 2025, 05:30 UTC

Résultats

Bayer Backs 2025 View

14 avr. 2025, 13:00 UTC

Actualités

Farmers' Favorite Weedkiller Nears Its End, Bayer Warns -- WSJ

7 avr. 2025, 17:01 UTC

Market Talk

Bayer Moves Forward in U.S. Roundup Litigation -- Market Talk

2 avr. 2025, 09:27 UTC

Actions en Tendance

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

10 mars 2025, 08:38 UTC

Market Talk

Bayer's Partial Recovery Is in Sight -- Market Talk

Comparaison

Variation de prix

Bayer AG prévision

Objectif de Prix

By TipRanks

0.53% hausse

Prévisions sur 12 Mois

Moyen 26.58 EUR  0.53%

Haut 33 EUR

Bas 20 EUR

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

13 ratings

3

Achat

10

Maintien

0

Vente

Score Technique

By Trading Central

22.99 / 23.88Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

139 / 538Classement par Finance

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.